134 related articles for article (PubMed ID: 22821368)
1. Regulatory forum opinion piece*: reversibility groups: the "hows" and "how-nots".
Ochoa R
Toxicol Pathol; 2013; 41(3):552-3. PubMed ID: 22821368
[TBL] [Abstract][Full Text] [Related]
2. Juvenile toxicity: are we asking the right questions?
Downes N
Toxicol Pathol; 2012 Jul; 40(5):830-7. PubMed ID: 22407308
[TBL] [Abstract][Full Text] [Related]
3. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals.
Buckley LA; Chapman K; Burns-Naas LA; Todd MD; Martin PL; Lansita JA
Int J Toxicol; 2011 Oct; 30(5):583-90. PubMed ID: 22013138
[TBL] [Abstract][Full Text] [Related]
4. Regulatory forum opinion piece: obligatory microscopic examination of intermediate dose groups in non-rodent toxicity studies--is it necessary?
Weddle DL; Mahrt CR; Schmidt SP
Toxicol Pathol; 2012 Jul; 40(5):826-9. PubMed ID: 22421750
[TBL] [Abstract][Full Text] [Related]
5. Regulatory forum opinion piece*: immunotoxicology assessments in nonhuman primates--challenges and opportunities.
Lebrec HN
Toxicol Pathol; 2013; 41(3):548-51. PubMed ID: 22886347
[TBL] [Abstract][Full Text] [Related]
6. Appropriate use of recovery groups in nonclinical toxicity studies: value in a science-driven case-by-case approach.
Pandher K; Leach MW; Burns-Naas LA
Vet Pathol; 2012 Mar; 49(2):357-61. PubMed ID: 21810619
[TBL] [Abstract][Full Text] [Related]
7. Juvenile animal toxicity study designs to support pediatric drug development.
Cappon GD; Bailey GP; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Ooshima Y; Stump DG; Hurtt ME
Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):463-9. PubMed ID: 20025047
[TBL] [Abstract][Full Text] [Related]
8. Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition.
Giri S; Bader A
Drug Discov Today; 2011 May; 16(9-10):382-97. PubMed ID: 21354326
[TBL] [Abstract][Full Text] [Related]
9. Stem cell models for drug discovery and toxicology studies.
Liu W; Deng Y; Liu Y; Gong W; Deng W
J Biochem Mol Toxicol; 2013 Jan; 27(1):17-27. PubMed ID: 23293059
[TBL] [Abstract][Full Text] [Related]
10. Toxicology testing in drug discovery and development.
Dorato MA; Buckley LA
Curr Protoc Toxicol; 2007 Feb; Chapter 19():Unit19.1. PubMed ID: 23045141
[TBL] [Abstract][Full Text] [Related]
11. Real life juvenile toxicity case studies: the good, the bad and the ugly.
De Schaepdrijver L; Rouan MC; Raoof A; Bailey GP; De Zwart L; Monbaliu J; Coogan TP; Lammens L; Coussement W
Reprod Toxicol; 2008 Sep; 26(1):54-5. PubMed ID: 18514481
[TBL] [Abstract][Full Text] [Related]
12. Target organ profiles in toxicity studies supporting human dosing: an assessment of recovery and chronic dosing.
Horner S; Robinson S; Lees D; Callander R; Roberts R
Regul Toxicol Pharmacol; 2014 Oct; 70(1):270-85. PubMed ID: 25020275
[TBL] [Abstract][Full Text] [Related]
13. Safety evaluation of biological drugs: what are toxicology studies in primates telling us?
Baldrick P
Regul Toxicol Pharmacol; 2011 Mar; 59(2):227-36. PubMed ID: 20937341
[TBL] [Abstract][Full Text] [Related]
14. Early clinical development: evaluation of drug-induced torsades de pointes risk.
Vik T; Pollard C; Sager P
Pharmacol Ther; 2008 Aug; 119(2):210-4. PubMed ID: 18601950
[TBL] [Abstract][Full Text] [Related]
15. Society of Toxicologic Pathology position paper on best practices on recovery studies: the role of the anatomic pathologist.
Perry R; Farris G; Bienvenu JG; Dean C; Foley G; Mahrt C; Short B;
Toxicol Pathol; 2013; 41(8):1159-69. PubMed ID: 23531793
[TBL] [Abstract][Full Text] [Related]
16. Evaluations of organ system development in juvenile toxicology testing.
Robinson K
Reprod Toxicol; 2008 Sep; 26(1):51-3. PubMed ID: 18595655
[TBL] [Abstract][Full Text] [Related]
17. Reducing attrition in drug development: smart loading preclinical safety assessment.
Roberts RA; Kavanagh SL; Mellor HR; Pollard CE; Robinson S; Platz SJ
Drug Discov Today; 2014 Mar; 19(3):341-7. PubMed ID: 24269835
[TBL] [Abstract][Full Text] [Related]
18. Opportunities to minimise animal use in pharmaceutical regulatory general toxicology: a cross-company review.
Sparrow SS; Robinson S; Bolam S; Bruce C; Danks A; Everett D; Fulcher S; Hill RE; Palmer H; Scott EW; Chapman KL
Regul Toxicol Pharmacol; 2011 Nov; 61(2):222-9. PubMed ID: 21855593
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of juvenile toxicity.
Barrow PC; Barbellion S; Stadler J
Methods Mol Biol; 2011; 691():17-35. PubMed ID: 20972745
[TBL] [Abstract][Full Text] [Related]
20. The future of preclinical animal models in pharmaceutical discovery and development: a need to bring in cerebro to the in vivo discussions.
Everitt JI
Toxicol Pathol; 2015 Jan; 43(1):70-7. PubMed ID: 25351920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
